Fanconi anemia complementation group N
MONDO:0012565Any Fanconi anemia in which the cause of the disease is a mutation in the PALB2 gene.
Also known as: FANCN, Fanconi Anemia, complementation group type N, Fanconi anaemia caused by mutation in PALB2, Fanconi anaemia complementation group type N, Fanconi anemia caused by mutation in PALB2, Fanconi anemia complementation group N, Fanconi anemia complementation group type N, PALB2 Fanconi anaemia
14 clinical trials for this condition and its sub-types, 2 tagged with Fanconi anemia complementation group N itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Which drug first? trial tests sequence of carboplatin and olaparib in aggressive prostate cancer
Disease control Recruiting nowResearchers are comparing two sequences of treatment for metastatic castration-resistant prostate cancer that carries certain DNA repair gene mutations. Participants receive either carboplatin first and olaparib second, or olaparib first and carboplatin second, switching after th…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Phase 1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC